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In 1936, bisphenol A (BPA) was reported to 
have the activity of an estrogenic drug (Dodds 
and Lawson 1936). Today, BPA is used in a 
large number of consumer products and is one 
of the highest volume chemicals produced, on 
the order of 8 billion pounds per year (Bailin 
et al. 2008). A large body of evidence now 
indicates that BPA is an endocrine-disrupting 
chemical that can induce a variety of adverse 
effects in mammals and other vertebrates and 
invertebrates (Oehlmann et al. 2008; Richter 
et al. 2007), but its safety continues to be dis-
puted (Goodman et al. 2009). Much remains 
to be determined about the mechanisms of 
action of BPA, which varies depending upon 
the dose, tissue, and life stage of exposure 
(vom Saal et al. 2007), but understanding 
the current levels of human exposure and the 
various routes of exposure to BPA, how BPA 
is metabolized, and whether animal mod-
els are relevant for modeling human expo-
sure is critical to better understand the risk 
posed to humans. The urgent need for this 
information is underscored by the Centers for 
Disease Control and Prevention’s conclusion 
that > 90% of people in the United States 
are chronically exposed to BPA (Calafat et al. 
2008) and the suggestion that this likely also 
applies to people living in other countries 
around the world (Vandenberg et al. 2010a).
Surprisingly, no available data directly 
bear on the question regarding sources and 
amounts of human exposure to BPA, and 
estimates of current daily BPA exposure lev-
els vary widely. The U.S. Food and Drug 
Administration (FDA) estimated that the 
daily BPA exposure level for adults in 2007 
was about 0.16 µg/kg/day (FDA 2008). 
However, after reviewing BPA levels reported 
in all available studies of human tissues, scien-
tists at a 2007 conference sponsored by the 
National Institute of Environmental Health 
Sciences predicted that exposure levels of 
> 35 mg/day (~ 500 µg/kg/day) would be 
required to account for the reported levels 
of BPA in adults (Vandenberg et al. 2007; 
vom Saal et al. 2007). This information was 
recently updated (Vandenberg et al. 2010a), 
and the models used for calculating human 
exposure, as well as the assumption that vir-
tually all BPA exposure is entirely from food 
and beverage containers, were sharply crit-
icized (Gies et al. 2009; Vandenberg et al. 
2010b).
Our understanding of current levels of 
human BPA exposure is complicated by our 
limited knowledge of the ways by which we 
are exposed. Because BPA leaches into food 
from plastic packaging and resin linings of 
food and beverage containers, it has been 
widely assumed that the consumption of con-
taminated food and beverages represents the 
major route of human exposure. However, 
new sources of exposure continue to be uncov-
ered, such as thermal (carbonless) receipts 
used for many daily transactions that contain 
a coating of high levels of free BPA, raising the 
possibility that dermal transport may also be 
a significant source of exposure (Biedermann 
et al. 2010; Environmental Working Group 
2010). There is signifi cant leaching of BPA 
from children’s books (Sajiki et al. 2010), and 
BPA is also present in cigarette filters, rais-
ing the concern that inhalation of cigarette 
smoke may be another previously unrecog-
nized source of exposure for individuals who 
smoke (Jackson and Darnell 1985).
In the absence of human pharmaco kinetic 
data for unconjugated (bioactive) BPA, find-
ings from studies in rodents and monkeys 
have been used to extrapolate to humans. The 
low BPA doses used in rodent studies lead 
to serum levels of unconjugated BPA signifi-
cantly below levels found in bio monitoring 
studies of men and pregnant and non pregnant 
women (Vandenberg et al. 2007), yet these 
low internal levels of BPA have been reported 
to result in numerous develop mental abnor-
malities (Richter et al. 2007). However, it has 
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Objective: Daily adult human exposure to bisphenol A (BPA) has been estimated at < 1 µg/kg, 
with virtually complete first-pass conjugation in the liver in primates but not in mice. We measured 
unconjugated and conjugated BPA levels in serum from adult female rhesus monkeys and adult 
female mice after oral administration of BPA and compared findings in mice and monkeys with 
prior published data in women.
MethOds: Eleven adult female rhesus macaques were fed 400 µg/kg deuterated BPA (dBPA) daily 
for 7 days. Levels of serum dBPA were analyzed by isotope-dilution liquid chromatography–mass 
spectrometry (0.2 ng/mL limit of quantitation) over 24 hr on day 1 and on day 7. The same dose 
of BPA was fed to adult female CD-1 mice; other female mice were adminis tered 3H-BPA at doses 
ranging from 2 to 100,000 µg/kg.
Results: In monkeys, the maximum unconjugated serum dBPA concentration of 4 ng/mL was 
reached 1 hr after feeding and declined to low levels by 24 hr, with no significant bioaccumulation 
after seven daily doses. Mice and monkeys cleared unconjugated serum BPA at virtually identical 
rates. We observed a linear (proportional) relationship between adminis tered dose and serum BPA 
in mice.
cOnclusiOns: BPA pharmacokinetics in women, female monkeys, and mice is very similar. By 
comparison with approximately 2 ng/mL unconjugated serum BPA reported in multiple human 
studies, the average 24-hr unconjugated serum BPA concentration of 0.5 ng/mL in both monkeys 
and mice after a 400 µg/kg oral dose suggests that total daily human exposure is via multiple routes 
and is much higher than previously assumed.
Key wORds: biomonitoring, bisphenol A, endocrine disruption, pharmacokinetics, xenobiotic 
metabolism. Environ Health Perspect 119:422–430 (2011). doi:10.1289/ehp.1002514 [Online 
20 September 2010]
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been argued that major metabolic differences 
between humans and rodents preclude extrapo-
lation of these data to humans (Dekant and 
Völkel 2008). Specifically, although glucuroni-
dation of BPA by uridine 5´-diphospho 
(UDP)-glucuronosyltransferases (UGTs) is a 
primary mode of phase II metabo lism in both 
rodents and primates, in adult primates BPA 
is cleared from the blood by the kidney into 
the urine (Figure 1), whereas in rodents the 
primary excretory pathway for BPA is via the 
bile into the feces (Inoue et al. 2005; Sakamoto 
et al. 2002). There may be other metabolic dif-
ferences between species; in the CD-1 mouse, 
glucuronidation includes the glucuronidation 
of both BPA and hydrox yl ated BPA (Zalko 
et al. 2003), but data on this are lacking for 
primates. The species differences in route of 
clearance have been interpreted as indicating 
that the value for clearance of unconjugated 
(bioactive) BPA must also be very different 
between rodents and primates.
To date, only a single study has attempted 
to examine BPA clearance rate from blood after 
a single oral administration in adult humans 
(Völkel et al. 2002). However, because the 
assay used in that study was not sufficiently 
sensitive to meas ure unconjugated serum 
BPA, only the concentration of conjugated 
BPA in human serum was reported. The study 
by Völkel et al. (2002) has been repeatedly 
cited as evidence for rapid clearance of uncon-
jugated serum BPA in adult humans, based 
on the assumption that the inability to detect 
unconjugated BPA with an insensitive assay 
indicated that all unconjugated BPA had been 
very rapidly metabolized. Thus, there has been 
strong criti cism concerning the use of this one 
study as the basis for this prediction (Gies et al. 
2009; Vandenberg et al. 2010a, 2010b). In 
the absence of data on the level of clearance of 
unconjugated BPA from human serum, it is an 
attractive option to use primates as surrogates 
to resolve questions about the relevance for 
humans of data from rodent studies.
Given the controversies and the unanswered 
questions about current levels of human 
external and internal exposure and the rate of 
BPA metabo lism, the objective of the study 
reported here was to compare the level of 
clearance of unconjugated (biologically active) 
BPA in an experi mental model with putative 
direct rele vance to humans (rhesus monkeys), 
and in a model used in dozens of published 
reports of adverse effects due to exposure to 
low doses of BPA (the CD-1/ICR mouse). In 
experiment 1, we used isotope-dilution liquid 
 chromatography–mass spectrometry (LC-MS) 
to determine the concentration of biologically 
active (unconjugated) as well as conjugated 
BPA in serum over the 24 hr after one or seven 
daily oral doses of 400 µg/kg/day deuterated 
BPA (dBPA) to adult female rhesus monkeys. 
Experiment 2, with adult female CD-1 mice, 
consisted of three parts. In experiment 2A, we 
administered a single 400 µg/kg/day oral dose 
of BPA, but we used 3H-BPA to ensure that 
we would be above the limit of quantitation 
(LOQ) throughout the 24 hr after adminis-
tra tion. In experiment 2B, we used 3H-BPA 
to examine the linear relation ship between 
adminis tered oral dose and serum concentration 
of unconjugated 3H-BPA over a 50,000-fold 
dose range (2 µg/kg to 100,000 µg/kg). In 
experiment 2C, we examined the concentration 
of uncon jugated and conjugated serum BPA 
over the 24 hr after adminis tration of 100,000 
µg/kg BPA and determined whether the results 
were 250-fold higher than those obtained using 
the 400 µg/kg/day dose of 3H-BPA. Finally, in 
experiment 3 we compared our data on conju-
gated serum BPA levels in monkeys and mice 
with prior published findings in adult women 
(Völkel et al. 2002). Our focus here is on 
unconjugated and conjugated BPA in serum. 
A more detailed analysis of BPA metabolites 
has been reported in CD-1 mice (Jaeg et al. 
2004; Zalko et al. 2003) and is currently being 
conducted in rhesus monkeys.
Materials and Methods
Animals. All animals used in these studies were 
treated humanely and with regard for allevia-
tion of suffering. All studies were conducted in 
accordance with National Institutes of Health 
guidelines (Institute of Laboratory Animal 
Resources 1996).
Monkeys. Eleven adult female rhesus 
macaques (Macaca mulatta) were housed at 
the California National Primate Research 
Center. Animals were caged individually with 
a 0600- to 1800-hour light cycle and at a 
temperature maintained at 25–27°C. Animals 
were fed a diet of Purina Monkey Chow 
(Purina-Mills, St. Louis, MO, USA) and water 
ad libitum. Seasonal produce, seeds, and cereal 
were offered as supplements for environ mental 
enrichment. Cages were made of stainless 
steel, and water was delivered to each cage 
by rigid poly vinyl chloride pipes and a water 
nipple. Only females with a history of normal 
menstrual cycles were selected for this study. 
Females ranged in age from 6 to 13 years, and 
body weights ranged from 6.17 to 8.95 kg 
(mean, 7.5 kg). Cephalic vein blood samples 
were collected from unanesthetized, cage- 
restrained animals that were trained to present 
an arm for the procedure. Animal protocols 
were reviewed and approved in advance by 
the Animal Care and Use Committee of the 
University of California–Davis. 
Mice. CD-1 mice were purchased from 
Charles River Laboratories (Wilmington, MA, 
USA) and maintained as an outbred stock 
(with periodic replacement) at the University 
of Missouri–Columbia. Animals were housed 
on corncob bedding in standard (11.5 × 
7.5 × 5 in.) poly propylene cages. Water was 
purified by reverse osmosis and carbon filtra-
tion and provided in glass bottles ad libitum. 
Pregnant and lactating females were fed Purina 
soy-based 5008 breeder chow and otherwise 
were maintained on Purina soy-based 5001 
maintenance chow (Purina-Mills). Rooms 
were kept at 25 ± 2°C under a 12:12-hr 
light:dark cycle. Animals were euthanized 
by CO2 asphyxiation and cervical disloca-
tion, after which blood was collected from 
the carotid and vertebral vessels. Animal pro-
cedures were approved by the University of 
Figure 1. Schematic diagram depicting the glucuronidation of BPA in the liver and the route of elimination 
of unconjugated BPA from serum in rodents and primates after initial absorption from the gut and trans-
port to the liver. There is evidence that entero hepatic recirculation in rodents has only a modest impact on 
unconjugated serum BPA (Pottenger et al. 2000).
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Missouri–Columbia Animal Care and Use 
Committee.
Statistical methods for calculation of 
pharmaco kinetic parameters. The following 
parameters were meas ured in monkeys and 
mice from the serum concentrations of BPA 
after oral adminis tration. The Cmax is the maxi-
mum concentration in serum. Our decision 
to use 0.5 hr as the first time of collection 
was based on the fact that in most prior stud-
ies this was reported as the time at which the 
maximum concentration was reached (Tmax). 
Our initial rate constant (Kinitial) was calcu-
lated from the slope of the natural log of the 
concentration versus the sample collection 
time. Kinitial was taken as the steepest rate of 
decay from the initial collection time points. 
The terminal phase elimination rate constant 
(Kterminal) was taken from the last three time 
points (between 4 and 24 hr for mice, between 
8 and 24 hr for monkeys, and between 12 and 
24 hr for humans). Half-lives (t½) were calcu-
lated as the natural log of 0.5 divided by the 
rate constant. The area under the curve (AUC) 
for the first 24 hr after dosing (AUC0–24) was 
calculated using the linear trapezoidal rule and 
the assumption that BPA in serum at the time 
just before administration (time 0) was zero. 
The AUC extrapolated to infinity (AUC0→∞) 
was calculated by dividing the concentra-
tion at 24 hr (the last time point meas ured) 
by the terminal rate constant and adding this 
term to the AUC0–24. We conducted day 1 
and day 7 comparisons for serum BPA con-
centrations in experiment 1 using Proc Mixed 
analysis of variance (ANOVA) with repeated 
measures followed by least-squares means in SAS 
(version 6.12; SAS Institute Inc., Cary NC, 
USA).
Experimental methods. Experiment 1: 
unconjugated and conjugated serum dBPA 
concentrations in rhesus monkeys. We used 
dBPA in experiment 1 because it can be clearly 
distinguished by isotope-dilution LC-MS, thus 
eliminating concern about potential BPA con-
tamination from materials used in the prepara-
tion, handling, or shipment of samples. The 
monkeys were fed 400 µg/kg body weight of 
dBPA, chosen based on the oral dose estimated 
to be required to achieve an average dBPA 
24-hr serum concentration in the range of 
1–2 ng/mL, which is the range typically found 
in bio monitoring studies of adult men and 
women (Vandenberg et al. 2010a). The LOQ 
was 0.2 ng/mL based on analysis of dBPA in 
approximately 1.5 mL serum. See Supplemental 
Material, Part 1 (doi:10.1289/ehp.1002514) 
for details of LC-MS analysis. 
Monkeys were fed 400 µg/kg body weight 
dBPA in food for 7 days. On the first and sev-
enth days of feeding, blood was collected over 
24 hr, with collection at 0 (pre feeding), 0.5, 1, 
2, 4, 8, 12, and 24 hr after feeding dBPA (each 
collection yielded ~ 1.5 mL serum). Blood was 
allowed to stand at room temperature for about 
15 min to clot (preliminary studies showed that 
no deconjugation of conjugated BPA occurred 
during this short time). Blood was then centri-
fuged at 1,800 × g for 10 min at 4°C. Serum 
was stored at –80°C and shipped overnight 
on dry ice from the University of California–
Davis to the University of Missouri–Columbia. 
The assays were conducted at the University of 
Missouri Veterinary Diagnostic Laboratory.
Experiment 2A: unconjugated serum 
3H-BPA concentrations in mice (400 µg/kg 
dose). Serum concentrations of unconjugated 
3H-BPA were examined in adult (~ 3 months 
of age) female CD-1 mice throughout the 
24 hr after administration of a 400 µg/kg oral 
dose dissolved in tocopherol-stripped corn oil. 
The volume delivered into the animal’s mouth 
via a micro pipetter (~ 30 µL) was adjusted to 
achieve a constant BPA dose per kilogram of 
body weight. Preliminary tests were performed 
to determine the volume of oil remaining in 
the pipette tip after dosing, and the total vol-
ume per mouse was adjusted to allow for this 
remaining amount. Mice were fed a 400 µg/kg 
dose of 3H-BPA instead of dBPA because of the 
limited amount of serum obtained from mice, 
which required a method with high sensitivity 
(Taylor et al. 2008). 3H-BPA (7.3 Ci/mmol, 
3.0 µCi/dose; Moravek Biochemicals, Brea, CA, 
USA) was mixed with unlabeled BPA (> 99% 
pure; Sigma-Aldrich, St. Louis, MO, USA) to 
achieve a final estimated concentration of 12 µg 
BPA/30 µL. The actual concentration adminis-
tered (12.1 µg/30 µL) and the specific activity 
(0.048 Ci/mmol) were determined from sam-
ples of the dosing solution. Blood was collected 
at 0.5, 1, 2, 3, 4, 6, and 24 hr after 3H-BPA 
administration, with five or six adult females 
at each time point. Serum was separated by 
centrifugation at 4°C and then stored at –20°C. 
Unconjugated 3H-BPA was measured in serum 
as described in the Supplemental Material, 
Part 1 (doi:10.1289/ehp.1002514).
Experiment 2B: relationship between BPA 
dose and unconjugated serum BPA concentra-
tion in mice. Adult (~ 3 months of age) female 
CD-1 mice were adminis tered a single oral dose 
of 3H-BPA mixed with different amounts of 
unlabeled BPA in tocopherol-stripped corn oil 
to achieve administered oral doses of 2, 20, 400, 
or 100,000 µg/kg body weight in approxi mately 
30 µL oil. Specifically, 3H-BPA was mixed with 
unlabeled BPA (> 99% pure; Sigma-Aldrich) 
to achieve the final concentrations. Samples of 
each solution were kept to meas ure the actual 
radio activity used in each dose; the final specific 
activities for each dose were calculated from 
these aliquots rather than from the theoreti-
cal radio activity per dose. The measured spe-
cific activities of the 2, 20, 400, and 100,000 
µg/kg solutions were 7.30, 0.87, 0.04, and 
0.0002 Ci/mmol, respectively, and the actual 
doses administered were 2.3, 20.1, 396.9, and 
Figure 2. Concentrations (mean ± SE) of unconjugated (A) and conjugated (B) dBPA in serum from adult female 
rhesus monkeys during the 24 hr after oral administration of 400 µg/kg body weight. Data represent the time 
course on day 1 (after one dose) and day 7 (after seven daily doses); n = 8–11 monkeys per time point.
*p < 0.005 for day 1 compared with day 7. 
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Table 1. Kinetic parameters for unconjugated and conjugated serum dBPA in adult female rhesus monkeys 
during the 24 hr after one (day 1) or seven (day 7) oral doses of dBPA (400 µg/kg).
Unconjugated Conjugated
Parameter Day 1 Day 7 Day 1 Day 7
Cmax (ng/mL) 3.95 4.40 149.47 226.96
Tmax (hr) 1 1 2 1
Kinitial (/hr) –0.70 –0.86 –0.26 –0.41
Initial t½ (hr) 0.99 0.81 2.64 1.69
Kterminal (/hr) –0.08 –0.10 –0.07 –0.04
Terminal t½ (hr) 8.88 7.20 10.08 17.92
AUC0–24 (ng-hr/mL)a 12.36 11.47 1068.67 1326.76
AUC0→∞ (ng-hr/mL) 13.44 11.87 1222.02 1893.75
Average AUC0–24 (ng/mL) 0.52 0.48 44.53 55.28
aConjugated:unconjugated AUC0–24 ratios: day 1, 86.47; day 7, 115.70.
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98,447 µg/kg, respectively. Because BPA was 
not soluble in oil at the highest concentration 
(120 mg/mL), it was instead administered as a 
suspension; radio activity in this suspension was 
comparable to that in the highest soluble con-
centration, as anticipated. Blood was collected 
24 hr after treatment, and serum was separated 
by centrifugation at 4°C and then stored at 
–20°C until analy sis for unconjugated 3H-BPA.
Experiment 2C: unconjugated and con-
jugated serum BPA concentrations in mice 
(100,000 µg/kg dose). Adult (~ 3 months 
of age) female CD-1 mice (four per group) 
were given a single oral dose of BPA (> 99% 
pure; Sigma-Aldrich) via a micro pipetter. The 
volume adminis tered (~ 30 µL) was adjusted 
to achieve a constant 100,000 µg BPA dose 
per kilogram of body weight. Blood was col-
lected at 0, 0.5, 1, 2, 3, 4, 6, or 24 hr after 
administration, and serum was separated by 
centrifugation at 4°C. Serum from the four 
mice in each group at each time point was 
pooled, and samples were stored at –20°C 
until analysis for unconjugated and conjugated 
BPA by high-performance liquid chroma-
tography (HPLC) with CoulArray detection 
(CoulArray 5600 detector; ESA, Chelmsford, 
MA, USA). See Supplemental Material, Part 1 
(doi:10.1289/ehp.1002514) for assay details.
Experiment 3: comparison of results from 
adult female monkeys and mice with data 
from women. We compared results from 
experiments 1 and 2C with data from a study 
by Völkel et al. (2002), which involved a single 
oral administration of dBPA (average adminis-
tered dose, 69.3 µg/kg) to adult men and 
women. The authors reported data for conju-
gated serum dBPA during the 24 hr after the 
single oral administration. We scaled the dose 
adminis tered to monkeys to the dose adminis-
tered to humans [based on accepted linearity of 
BPA pharmaco kinetics with dose (Doerge et al. 
2010a; Vandenberg et al. 2007)] by multi-
plying the monkey serum-conjugated dBPA 
values at each time point by a factor of 0.173 
(69.3/400 µg/kg). We scaled the dose adminis-
tered to mice (a single 100,000 µg/kg dose 
of BPA) to the dose adminis tered to humans 
by multiplying the mouse serum–conjugated 
BPA values at each time point by a factor of 
0.000693 (69.3/100,000 µg/kg). We used 
GraphClick (version 3.0; Arizona Software 
2008) to capture data and calculate the AUC 
for women by integration of the curve fit equa-
tion presented by Völkel et al. (2002) in their 
Figure 7. 
Results
Experiment 1: unconjugated and conjugated 
serum dBPA concentrations in rhesus monkeys. 
In this experiment, we determined the con-
centrations of unconjugated and conjugated 
dBPA in 11 adult female rhesus monkeys over 
a 24-hr period after a single oral 400 µg/kg 
dose of dBPA and compared the data after 
one adminis tration with data from the same 
animals after seven daily oral adminis trations. 
The results for unconjugated and conjugated 
dBPA on days 1 and 7 (Figure 2) reveal that 
the serum levels of unconjugated dBPA were 
very similar after a single oral dose and after 
seven doses, indicating that bio accumulation 
of parent dBPA did not occur in response to 
a single oral exposure each day (the AUC0–24 
was virtually identical for days 1 and 7; 
Table 1). Our findings show that the maxi-
mum attained value (Cmax) for unconjugated 
dBPA in serum at 1 hr after feeding was 
3.95 ng/mL on day 1 and was 4.40 ng/mL 
on day 7 (Table 1). By 24 hr after administra-
tion, unconjugated dBPA remained above our 
LOQ (0.2 ng/mL; ppb) for 5 of the 11 females 
on day 1 and for 4 of 11 females on day 7. The 
AUC0–24 for unconjugated serum dBPA on 
day 1 was 12.36 ng-hr/mL and on day 7 was 
11.47 ng-hr/mL. The Kterminal for conjugated 
dBPA on day 7 (–0.04/hr) was somewhat 
slower than on day 1 (–0.07/hr). Only at 1 hr 
after oral administration was the concentration 
of conjugated serum dBPA significantly higher 
on day 7 than on day 1 (p < 0.005; Figure 2). 
Over all time points, however, we observed no 
significant difference between day 1 and day 7 
in serum-conjugated dBPA. The AUC0–24 
ratio for conjugated/unconjugated serum 
dBPA was 116 on day 7 and 87 on day 1.
Experiment 2A: unconjugated serum 
3H-BPA concentrations in mice (400 µg/kg 
dose). In this experiment we determined the 
serum concentration of unconjugated 3H-BPA 
in adult female CD-1 mice over the 24 hr after 
oral administration of the same 400 µg/kg dose 
used in experiment 1 with adult female rhesus 
monkeys. The serum concentration of unconju-
gated 3H-BPA in the mice is shown in Figure 3 
in relation to the data from experiment 1 for 
unconjugated dBPA in female rhesus monkeys 
over the 24-hr time period after treatment. The 
calculated parameters for the mice are shown 
in Table 2. For unconjugated serum 3H-BPA 
in mice, the Cmax was 3.28 ng/mL at 1 hr 
(Tmax). AUC0–24 for unconjugated 3H-BPA 
was 16.72 ng-hr/mL, a low value that was 
similar to the value obtained for the monkeys 
adminis tered the same dose and time period 
(12.36 ng-hr/mL). Because we did not have an 
authentic standard for either BPA glucuronide 
or BPA sulfate, the two expected BPA conju-
gates, we did not attempt to quantify conju-
gated serum 3H-BPA in this experi ment.
Experiment 2B: relationship between 
3H-BPA dose and unconjugated serum 
3H-BPA concentration in mice. The objec-
tive of experi ment 2B was to determine the 
relation ship between adminis tered oral dose 
and serum concentration of 3H-BPA in adult 
female CD-1 mice meas ured 24 hr after BPA 
dosing. In more detail, the results shown in 
Figure 4 reveal that oral administration of a 
single dose of 3H-BPA at 2–100,000 µg/kg 
resulted in a linear relationship (R2 = 0.9807) 
between the adminis tered dose and the serum 
concentration of unconjugated 3H-BPA 24 hr 
after adminis tration (based on a log–log plot). 
Thus, these results provide evidence for a linear 
relationship between doses and unconjugated 
serum BPA concentrations in mice.
Experiment 2C: unconjugated and conju-
gated serum BPA concentrations in mice fed a 
single dose of 100,000 µg/kg. In experiment 2B 
we observed a linear relationship between the 
adminis tered dose of BPA and unconjugated 
serum BPA over a 50,000-fold dose range 
Figure 3. Concentrations (mean ± SE) of uncon-
jugated serum BPA during the 24 hr after oral 
adminis tration of 400 µg/kg 3H-BPA to adult female 
CD-1 mice (n = 5–7 per time point) and 400 µg/kg 
dBPA to adult female rhesus monkeys (n = 10–11 
per time point).
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Table 2. Kinetic parameters for serum BPA in adult female CD-1 mice during the 24 hr after a single oral 
dose of 400 µg/kg or 100,000 µg/kg 3H-BPA.
400 µg/kg dose 
(unconjugated)
100,000 µg/kg dose
Parameter Unconjugated Conjugated
Cmax (ng/mL) 3.28 949.14 114151.86
tmax (hr) 1 1 1
Kinitial (/hr) –0.71 –0.77 –0.66
Initial t½ (hr) 0.97 0.90 1.05
Kterminal (/hr) –0.02 –0.14 –0.17
Terminal t½ (hr) 33.64 4.90 4.07
AUC0–24 (ng-hr/mL)a 16.72 2936.37 367887.45
AUC0–∞ (ng-hr/mL) 38.72 2990.87 371418.70
Average AUC0–24 (ng/mL) 0.70 122.35 15328.64
Scaled average AUC0–24 (ng/mL)b 0.49 61.32
aConjugated/unconjugated AUC0–24 ratio = 125.29 ng-hr/mL. bAUC 100,000 µg/kg was scaled to 400 µg/kg by dividing by 250. 
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(2–100,000 µg/kg). Here we sought to deter-
mine whether adult female CD-1 mice fed a 
100,000 µg/kg dose showed the serum con-
centrations of unconjugated BPA predicted by 
linear extrapolation when adjusted to a dose 
of 400 µg/kg by dividing all serum concentra-
tions by a scaling factor of 250. Because of the 
high dose administered, instead of 3H-BPA we 
used a chemical analysis method (HPLC with 
CoulArray detection) to determine the uncon-
jugated and conjugated concentrations of BPA. 
This approach allowed comparison of the use 
of 3H-BPA and authentic BPA on determina-
tion of serum concentrations of BPA over the 
24 hr after oral adminis tration.
The average values for unconjugated and 
conjugated BPA over the 24 hr after a single 
oral dose of 100,000 µg/kg are shown in 
Figure 5 and Table 2. When we extrapolated 
(scaled) the 100,000 µg/kg dose to 400 µg/kg 
(by dividing each serum BPA value by 250) for 
comparison with the data from adult female 
mice adminis tered 400 µg/kg 3H-BPA, uncon-
jugated serum values of BPA and 3H-BPA 
over the 24 hr after a single feeding were not 
significantly different (Figure 6). This finding 
reveals that the data for 3H-BPA determined 
by HPLC separation and scintillation counting 
were virtually identical to what would be pre-
dicted based on analysis of BPA by HPLC with 
CoulArray detection. This finding also pro-
vides additional evidence for linearity between 
adminis tered dose and unconjugated serum 
BPA in adult female mice throughout the 
entire 24-hr period after oral adminis tration.
Experiment 3: serum concentrations of 
conjugated BPA in monkeys and mice com-
pared with data from women. The study by 
Völkel et al. (2002) involved a single oral dose 
of dBPA (average, 69.3 µg/kg) to adult men 
and women. The assay the authors used lacked 
the sensitivity required to meas ure unconju-
gated dBPA; thus, they reported only data for 
conjugated serum dBPA during the 24 hr after 
the single oral adminis tration (Völkel et al. 
2002). Because we observed a linear relation-
ship between adminis tered BPA dose and 
serum levels of BPA in adult female mice in 
experiments 2B and 2C using two different 
approaches, and because dose proportionality 
for total serum BPA has also been reported 
in rats (Doerge et al. 2010b), we compared 
the data by Völkel et al. (2002) for serum-
conjugated dBPA in women with our data for 
rhesus monkeys and CD-1 mice. The BPA 
dose adminis tered to monkeys was scaled to 
the human dose by multiplying the mon-
key serum-conjugated dBPA values at each 
time point by 0.173 (69.3/400 µg/kg). The 
BPA dose adminis tered to mice, from experi-
ment 2C in which mice were fed a single 
100,000 µg/kg dose of BPA, was scaled to the 
human dose multiplying the mouse serum-
conjugated BPA values at each time point by a 
factor of 0.000693 (69.3/100,000 µg/kg).
We used only the data for women reported 
by Völkel et al. (2002) (these are the only avail-
able data for women) because rodent data sug-
gest that sex differences related to background 
levels of testosterone may alter the metabolism 
of BPA (Shibata et al. 2002; Takeuchi et al. 
2006) and because there are differences in total 
BPA in urine btween men and women (Calafat 
et al. 2008). In addition, the data of Völkel 
et al. (2002) differed for men and women at 
24 hr (see their Figure 7). 
The data comparing women, adult female 
monkeys, and adult female mice, presented 
in Figure 7 and Table 3, reveal that for the 
women examined by Völkel et al. (2002) and 
the adult female rhesus monkeys and mice that 
we examined, the kinetics were very similar 
for conjugated BPA in serum. In calculating 
the AUC data in Table 3, we used only data 
between 4 and 24 hr for women, monkeys, 
and mice because Völkel et al. (2002) did not 
report results for women before 4 hr. Therefore, 
we were also able to compare directly only 
the Kterminal values and not the Kinitial values. 
However, in Figure 7 we show all of our data 
for rhesus monkeys and mice, including the 
results for time points before 4 hr, although 
data from collections before 4 hr were not used 
in the analyses shown in Table 3.
The SE for serum-conjugated dBPA for 
women and female monkeys overlapped at 
every time point examined (Figure 7). The 
absence of a difference in these data among 
women, monkeys, and mice was reflected in 
the similarity in values for the AUC between 
4 and 24 hr after feeding (AUC4–24; Table 3). 
Importantly, the data for mice were similar to 
those for women and monkeys between 4 and 
24 hr after a single feeding (Figure 7, Table 3).
Discussion
In this study in rhesus monkeys, an experimen-
tal model with direct rele vance to humans, we 
assessed the serum concentrations of uncon-
jugated (biologically active) and conjugated 
dBPA over the 24-hr period after oral expo-
sure to 400 µg/kg dBPA predicted on the 
basis of biomonitoring studies to be rele vant 
to human exposure levels (Vandenberg et al. 
2007, 2010b; vom Saal et al. 2007). We then 
evaluated the relevance of a rodent model for 
primates by comparing the level of clearance of 
unconjugated BPA from serum in the mouse 
compared with the rhesus monkey. Because 
marked differences between rodents and pri-
mates have been predicted (Goodman et al. 
2009), these experiments directly address 
two central issues that have been controver-
sial: a) the rate at which unconjugated BPA 
is cleared from serum in rhesus monkeys and 
mice, and b) the oral dose of BPA necessary in 
rhesus monkeys and mice to achieve serum lev-
els of unconjugated BPA found in numerous 
biomonitoring studies in humans.
Metabolism of oral BPA in monkeys and 
mice. An often-stated assumption is that 
humans rapidly conjugate all ingested BPA, 
primarily via the action of UGT (Figure 1) 
during the first pass of BPA through the liver. 
(BPA is rapidly absorbed from the intestines 
Figure 4. Concentration of unconjugated serum 
3H-BPA in adult female CD-1 mice in relation to the 
administered oral dose of BPA over a 50,000-fold 
dose range (nominal dose: 2, 20, 400, and 100,000 
µg/kg). Blood was collected 24 hr after adminis tra-
tion of BPA. y = 0.0017x0.9798; R 2 = 0.9807.
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Figure 6. Concentration of unconjugated serum 
BPA in adult female CD-1 mice during the 24 hr 
after a single dose of 400 µg/kg 3H-BPA or 100,000 
µg/kg BPA. The data for the 100,000-µg/kg dose are 
extrapolated (scaled) to the 400 µg/kg data based 
on the demon strated linear relationship between 
serum BPA and dose administered (Figure 4).
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and transported to the liver via the portal ves-
sels leading directly from the gut to the liver.) 
Of great importance, our findings demon-
strate that the first-pass metabolism of par-
ent BPA after oral administration in rhesus 
monkeys is not rapid or complete. In addi-
tion, our results show that the mean uncon-
jugated serum dBPA concentrations at both 
8 hr (0.35 ng/mL) and 12 hr (0.15 ng/mL) 
after one oral administration of 400 µg/kg 
dBPA were both well within the biologically 
active range of BPA in human tissues and cells 
(Hugo et al. 2008; Wetherill et al. 2002).
These data directly contradict state-
ments made in reviews funded by the 
Polycarbonate/BPA Global Group (Dekant 
and Völkel 2008; Goodman et al. 2009). For 
example, Goodman et al. (2009) stated that 
“orally administered BPA is subject to exten-
sive (≥ 99%) first-pass detoxifying metabo-
lism.” These authors cited Völkel et al. (2002) 
as the basis for the conclusion that there was 
little concern for human health due to expo-
sure to BPA. The prediction of rapid and com-
plete first-pass elimination of parent BPA in 
adult humans is based on a single study of 
BPA metabolism in humans after one oral dose 
(Völkel et al. 2002). In that study using three 
women and six men, the LOQ was > 10 times 
higher than in other published studies using 
the same techniques (reviewed by Vandenberg 
et al. 2010a). Because the assay used by Völkel 
et al. (2002) was unable to detect unconju-
gated BPA in serum, the authors made predic-
tions regarding the kinetics of unconjugated 
BPA in the absence of data. We also note that 
if the data presented in Figure 7 of Volkel 
et al. (2002) are reanalyzed with the inclusion 
of the 24-hr time point for men (a value that 
was excluded without explanation) and using 
conjugated rather than total BPA values for 
all time points, the terminal half-life increases 
from the reported value of 3.4 hr to 6.0 hr. 
Our results thus provide compelling evidence 
that assumptions about the rate of BPA metab-
olism in humans based on the study by Völkel 
et al. (2002) are inaccurate; this is consistent 
with similar conclusions reached by others 
(Gies et al. 2009; Vandenberg et al. 2010b).
Oral doses of BPA required to achieve 
measured human serum levels. The second 
major issue of contention concerns estimates 
regarding the amount, as well as the route 
of exposure, required to account for BPA 
levels between 0.3 and 4 ng/mL detected 
in human serum and urine in biomonitor-
ing studies. The prediction that intermittent 
oral exposure accounts for virtually all expo-
sure to BPA by adults is clearly not consis-
tent with these findings or a large number 
of other published studies (Vandenberg et al. 
2010a). Specifically, in our study with rhesus 
monkeys, we were required to adminis ter a 
relatively high (400 µg/kg) dBPA oral dose 
compared with predicted human BPA oral 
exposure of < 1 µg/kg/day to achieve serum 
concentrations similar to those reported in 
biomonitoring studies. However, our dBPA 
dose resulted in a relatively low 24-hr average 
serum concentration of bioactive (unconju-
gated) dBPA (0.52 ng/mL) and a maximum 
value of 3.95 ng/mL 1 hr after administra-
tion. These findings should be considered in 
relation to numerous bio monitoring stud-
ies reporting median levels of 0.3–4 ng/mL 
unconjugated BPA in serum from men and 
women (Vandenberg et al. 2010a). 
Only a few authors have rejected data from 
human biomonitoring studies (Dekant and 
Völkel 2008; Doerge et al. 2010b; Goodman 
et al. 2009). This rejection is based on the 
assumption that data demonstrating BPA 
levels inconsistent with exposure models that 
presume that humans ingest < 1 µg/kg/day 
BPA must have involved the use of contami-
nated equipment that was the source of the 
meas ured BPA. Although those making this 
claim report substantial laboratory BPA con-
tamination in the range of ≥ 2 ng/mL (Doerge 
et al. 2010a; Völkel et al. 2002), most of the 
studies being rejected included explicit and 
appropriate controls for contamination and 
measured and reported low to undetectable 
background BPA, and thus a low LOQ, which 
is also the case for our studies (reviewed by 
Vandenberg et al. 2010b). Several of the stud-
ies also detailed the steps taken to achieve a 
low to undetectable background contamina-
tion. Thus, other reasons, such as selectivity 
of the analytical technique, would be required 
to support the hypothesis of over estimation of 
human plasma BPA levels.
Our findings thus provide experimental 
support for the prediction made in the National 
Institutes of Health–sponsored Chapel Hill 
Consensus Statement (Vandenberg et al. 2007; 
vom Saal et al. 2007) that, to account for the 
published concentrations of unconjugated 
serum BPA in adult men and women, daily 
oral doses of BPA would have to be at least 
Figure 7. Concentration of conjugated dBPA or BPA in serum from adult female rhesus monkeys, CD-1 
mice, and humans during the 24 hr after one oral dose. Women were administered an average dose 
of 69.3 µg/kg dBPA (Völkel et al. 2002). Rhesus monkeys were administered 400 µg/kg dBPA and mice 
were administered 100,000 µg/kg BPA; results for monkeys and mice were scaled to 69.3 µg/kg, based 
on evidence for linear kinetics and because in mice the administered dose was linear with serum BPA 
between 2 and 100,000 µg/kg (Figure 4). Both nanomolar and nanograms per milliliter data are presented 
for compari son with the human data of Völkel et al. (2002).
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Table 3. Kinetic parameters for conjugated dBPA in serum during the 24 hr after administration of 69.3 µg/kg 
dBPA to adult women (Völkel et al. 2002), compared with data from rhesus monkeys and CD-1 mice in the 
present study. 
Kinetic parameter, day 1 Women Monkeys Mice
Concentration at 4 hr [ng/mL (SE)] 24.05 (9.52) 19.82 (7.52) 10.17
Kterminal (/hr) –0.18 –0.07 –0.17
Terminal t½ (hr) 3.76 10.08 4.07
AUC4–24 [ng-hr-mL (SE)] 148.51 (25.42) 96.91 (18.91) 134.1
Average AUC4–24 (ng/mL) 7.43 4.85 6.7
The terminal t½ in women (n = 3) is based on data from Völkel et al. (2002; see their Figure 7) and is expressed 
in hours instead of minutes. The Kterminal was from 16 to 24 hr for women, 12 to 24 hr for monkeys, and from 6 
to 24 hr for mice. Data presented here are for between 4 and 24 hr because Völkel et al. (2002) did not report 
data for women before 4 hr. Monkey and mouse data were scaled to 69.3 µg/kg from the single dose of 400 µg/kg 
dBPA fed to monkeys and 100,000 µg/kg BPA fed to mice. No variance estimates (SEs) are available from the mouse 
study (experiment 2C) because serum samples were pooled for each time point.
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500 µg/kg (Vandenberg et al. 2007, 2010b). 
The high end of the range of median values 
reported for unconjugated BPA in human 
serum corresponds to the highest levels we 
saw only briefly in rhesus females after the 
oral adminis tration of 400 µg/kg/day, a dBPA 
dose 8 times higher than the current U.S. 
Environmental Protection Agency’s “safe” daily 
intake dose of 50 µg/kg/day (U.S. EPA 1988). 
Thus, if serum BPA concentrations in humans 
are actually between 0.3 and 4 ng/mL, our data 
raise grave concern that regulatory agencies have 
grossly under estimated current human exposure 
levels because they have relied on the predic-
tion of Völkel et al. (2002) that nearly total 
first-pass metabolism will ensure that bioactive 
BPA is not present in human sera, when in fact 
multiple human biomonitoring studies have 
established this to be false.
On the basis of our findings, we propose 
that the higher-than-predicted serum levels of 
unconjugated BPA in men and women reflect 
significant non oral BPA exposure in addi-
tion to oral exposure. This is consistent with 
other evidence suggesting that the consump-
tion of BPA-contaminated food and beverages 
alone is insufficient to account for the BPA 
levels reported in human bio monitoring stud-
ies (Vandenberg et al. 2010b); this includes 
data from the National Health and Nutrition 
Examination Survey (NHANES) conducted by 
the Centers for Disease Control and Prevention 
(Stahlhut et al. 2009). A significant data gap is 
the absence of a comprehensive list of products 
containing BPA. Of particular concern is infor-
mation about sources of non oral exposures that 
would lead to higher serum BPA concentrations 
relative to oral exposures (no hepatic first-pass 
effect), because unconjugated serum BPA levels 
are higher in adults after non oral exposure than 
after oral exposure (Vandenberg et al. 2007). 
One example of a recently identified source 
of human exposure to BPA is thermal paper 
receipts that could potentially result in trans-
dermal exposure (Biedermann et al. 2010).
Kinetics of metabolism in monkeys and 
mice, and comparison with prior data from 
women. After an oral BPA dose of 400 µg/kg, 
the serum concentrations of BPA in adult 
female CD-1 mice and rhesus monkeys were 
very similar. However, the average concen-
tration of unconjugated BPA in serum over 
the 24 hr after adminis tration to both mice 
and rhesus monkeys (based on the average 
AUC0–24) was about 0.5 ng/mL, which is at 
the low end of the median concentrations of 
unconjugated serum BPA (range, 0.3–4.4 
ng/mL, or 1–19.4 nM) in men and women 
(Vandenberg et al. 2010a). These findings thus 
contradict an important assumption made 
by U.S. and European regulatory agencies, 
namely, that rodents and primates are pre-
dicted to show markedly different clearance 
levels of BPA from serum. Importantly, this 
assumption has been central to the argument 
that rodent studies are not relevant to primates 
(including humans) for assessing the safety of 
BPA (reviewed by Gies et al. 2009). Our data 
(Figure 7) demon strate the similarity in the 
rate of phase II BPA metabolism (based on 
conjugated BPA in serum) for humans, rhesus 
monkeys, and mice.
Some authors have emphasized the impor-
tance of entero hepatic recirculation in rodents 
as a critical factor that results in higher serum 
levels of unconjugated BPA relative to pri-
mates after a similar oral dose (Teeguarden 
et al. 2005). In fact, the data presented here 
(Figures 3 and 5) show a very slight increase in 
unconjugated serum BPA in adult female mice 
(but not rhesus monkeys; Figure 2) between 
4 and 6 hr after oral administration of BPA 
at 400 µg/kg and 100,000 µg/kg. A similar 
small but not statistically significant increase in 
unconjugated serum BPA between 4 and 6 hr 
after oral administration of BPA in rats has been 
reported by others (Pottenger et al. 2000). 
Taken together, the data do not support 
the contention that entero hepatic recircula-
tion of BPA is a major factor that justifies 
disregarding findings from rodent studies in 
assessing the potential risks to humans posed 
by doses of BPA thousands of times lower 
than the assumed lowest observed adverse 
effect level of 50 mg/kg/day, the level that 
was used to calculate the reference dose of 
50 µg/kg/day (U.S. EPA 1988). In addi-
tion, the recog nized difference in route of 
clearance of BPA between rodents (primar-
ily via the feces) and primates (primarily via 
the urine) has also been incorrectly inter-
preted as supporting the prediction of a dif-
ferent level of clearance of BPA. Our data 
clearly demonstrate that, in rhesus monkeys 
and mice, the rate of clearance of unconju-
gated BPA from serum during the 24 hr after 
oral BPA adminis tration is virtually identi-
cal. These findings are consistent with those 
of Tominaga et al. (2006), who reported 
pharmaco kinetic differences between cyno-
molgus monkeys and rats during the first 4 hr 
after BPA administration but no difference in 
the 24-hr average BPA serum concentration 
(based on the average AUC0–24).
Relationship between administered and 
internal dose of BPA, and age-related changes 
in BPA pharmacokinetics. Our studies also 
provide data on the relationship between 
adminis tered dose of BPA and unconjugated 
serum BPA. In adult female mice, we found 
this relation ship to be linear over a wide range 
of adminis tered oral doses (particularly between 
2 and 400 µg/kg). This finding was predicted 
based on numerous studies in rats (Vandenberg 
et al. 2007). A practical reason for examin-
ing this relation ship is that researchers need 
to know whether it is necessary to determine 
the internal concentration of BPA for every 
dose adminis tered or if they are potentially 
able to extrapolate from data obtained with a 
high dose to predict internal dose in response 
to low adminis tered doses of BPA; it is dif-
ficult to meas ure very low concentrations of 
BPA in the limited amount of serum obtained 
from mice or any young rodent. Our previous 
study (Taylor et al. 2008), in which we com-
pared unconjugated serum 3H-BPA after oral 
administration and subcutaneous injection in 
newborn mice (where it is difficult to meas ure 
very low concentrations of BPA in the limited 
amount of serum obtained), also revealed lin-
earity of serum BPA with adminis tered dose 
regardless of route of administration. 
A final important issue concerns the com-
pari son of BPA metabolism in infant and 
adult rodents and rhesus monkeys. We previ-
ously reported that the AUC0–24 for 3-day-
old CD-1 female mice fed 395 µg/kg/day 
3H-BPA in oil was 66.7 ng-hr/mL, with a 
Cmax of 14.8 ng/mL (Taylor et al. 2008). Our 
data here show a 4-fold decrease in the AUC 
and a 4.5-fold decrease in Cmax in adult female 
CD-1 mice adminis tered an oral dose of 
400 µg/kg BPA (Table 2), reflecting the more 
rapid metabo lism of BPA in adults relative to 
newborn mice. Consistent with these findings, 
UGT activity toward BPA between post natal 
days 3 and 21, when adult levels of metabo-
lism are reached, was shown to increase 4-fold 
in Wistar rats, which would result in adults 
conjugating BPA 4 times faster than infants 
(Matsumoto et al. 2002).
In contrast to our findings with CD-1 
mice, Doerge et al. (2010a) reported a mark-
edly different change in the rate of uncon-
jugated BPA clearance between birth and 
adulthood in the FDA National Center for 
Toxicological Research’s (NCTR) CD-SD 
rat, with a 20.5-fold decrease in AUC and a 
74.4-fold decrease in Cmax for unconjugated 
BPA between postnatal day 3 and adult hood. 
In a companion study with rhesus monkeys, 
Doerge et al. (2010b) also provided evidence 
for an age-related decrease in AUC (3.8-fold) 
and Cmax (2.7-fold) for unconjugated BPA 
between 5-day-old rhesus monkeys and 
adults, changes similar in magnitude to those 
in CD-1 mice based on data in the present 
study and our previous study (Taylor et al. 
2008). However, the rhesus monkey study by 
Doerge et al. (2010b) involved a small number 
of animals, and the age-related differences were 
reported to not reach statistical significance. 
Thus, although Doerge et al. (2010b) found 
evidence for approxi mately a 4-fold change in 
the rate of metabo lism of unconjugated BPA 
between infants and adults after oral expo-
sure in rhesus monkeys, they concluded that 
“there was no evidence for diminished Phase II 
metabolism” in infants. 
In the present study and in our prior study 
in neo natal mice (Taylor et al. 2008), we used 
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CD-1/ICR mice, the model animal used by the 
National Toxicology Program and in > 20 pub-
lished studies from different laboratories report-
ing adverse effects of BPA (reviewed by Myers 
et al. 2009; Richter et al. 2007). The conclu-
sion by Doerge et al. (2010b) that “pharma-
cological effects observed in early post natal rats 
could over predict those possible in primates 
of the same age” may thus be accurate only 
for the NCTR CD-SD strain of rat, a strain 
derived from the CD-SD rat (Latendresse et al. 
2009) that, in contrast to the CD-1 mouse, has 
not shown low-dose effects of BPA in many 
toxicological studies (reviewed by vom Saal and 
Hughes 2005). Our present findings clearly 
demon strate that adult CD-1 mice and rhe-
sus monkeys show virtually identical clearance 
of unconjugated BPA from serum over the 
24 hr after a single oral administration, and 
that both the mouse and the monkey are very 
simi lar to humans in serum-conjugated BPA 
over the 24 hr after administration of the same 
dose (Figure 7). Our findings support the con-
sensus report on BPA from a meeting held 
by the German Federal Environment Agency 
(Umweltbundesamt) (Gies et al. 2009) that 
rodents are appropriate models for predicting 
serum levels of bioactive BPA in primates.
Many claims have been made concerning 
the lack of relevance of rodents for predict-
ing the consequences of BPA exposure for 
primates, including humans. A large number 
of low-dose studies reporting adverse effects 
of BPA in mice have involved adminis tered 
doses that our findings here and elsewhere 
(Taylor et al. 2008) show result in internal 
doses of unconjugated BPA that are already 
far exceeded by those found in multiple 
biomonitoring studies in humans (reviewed 
by Richter et al. 2007; Vandenberg et al. 
2007, 2010a). For example, based on linearity 
of administered and internal dose, a 20 µg/kg 
oral dose of BPA is predicted to lead to an 
average serum concentration over 24 hr of 
about 0.04 ng/mL BPA in adult CD-1 mice 
(Table 2). This 20 µg/kg/day oral dose of BPA 
caused adverse effects in adult mice as well as 
in adult rats (Alonso-Magdalena et al. 2006; 
Bindhumol et al. 2003; Sakaue et al. 2001; 
reviewed by Richter et al. 2007). Assertions 
that low-dose rodent studies involving both 
develop mental and adult exposures are irrele-
vant for predicting the risk posed by BPA to 
human health are misguided. These assertions 
also ignore a large body of literature showing 
that BPA has equal potency in both rodent 
and human cells (Welshons et al. 2006).
Conclusions
Many studies have attempted to portray the 
inability to detect unconjugated serum BPA 
in one experi ment conducted with a limited 
sample size and a relatively insensitive assay 
(Völkel et al. 2002) as an indication that all 
administered BPA is completely metabolized 
during its first pass through the liver. Our find-
ings with rhesus monkeys in the present study 
do not support this conclusion and indicate 
that the adult rhesus monkey is a valid model 
for predicting the serum levels of conjugated 
BPA after oral exposure in humans. Our find-
ings also suggest that the mouse is a valid pre-
dictor of serum-conjugated BPA after oral 
exposure in humans. Finally, when the data 
on BPA metabo lism in infant and adult rhesus 
monkeys reported in an FDA study (Doerge 
et al. 2010b) are compared with our findings 
in neonatal CD-1 mice (Taylor et al. 2008) 
and our data presented here, virtually identical 
age-related changes in the rate of metabo lism of 
unconjugated BPA are evident in rhesus mon-
keys and CD-1 mice. These findings lead to 
the conclusion that the CD-1 mouse is a valid 
predictor of age-related changes in the rate of 
metabolism of BPA in rhesus monkeys and 
thus also likely in humans. Finally, ingestion of 
the currently estimated exposure level of BPA 
from food and beverages in the United States 
(0.16 µg/kg/day) is not consistent with our 
finding here of an average serum-unconjugated 
BPA concentration of about 0.5 ng/mL in 
rhesus monkeys and mice during the 24 hr after 
ingestion of 400 µg/kg/day BPA.
cORRectiOn
In the manuscript originally published 
online, Pierre-Louis Toutain and Céline M. 
Laffont were omitted from the list of 
authors; there were calculation errors in 
Tables 1–3; and the y-axis for unconjugated 
BPA in Figure 5 was incorrect. All of these 
have been corrected here.
In Supplemental Material, Part 2 
(doi:10. 1289/ ehp.1002514), the authors 
have included the original data as mean, 
SE, and number of animals per treat-
ment group, as well as analy sis of the data 
from these experiments using WinNonlin 
(Pharsight Corporation, Cary, NC, USA) 
and NONMEM (ICON Development 
Solutions, Ellicott City, MD, USA) soft-
ware that is used by the Food and Drug 
Administration for analyzing pharmaco-
kinetic data.
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